“Dramatic” Responses with Targeted Agent for Patients with CLL

A 22-month survival in 96% of treatment-naïve patients
February 2013 Vol 6, No 1, Special Issue - Leukemia
Charles Bankhead

Atlanta, GA—Targeting Bruton’s tyrosine kinase (BTK) in patients with chronic lymphocytic leukemia (CLL) resulted in high response rates, without severe toxicity, according to the results of 2 studies that were presented at the 2012 ASH meeting.

Data from one trial showed a 70% response rate in 116 patients treated with ibrutinib and a 22-month survival of 96% in previously untreated patients and 76% in the subgroup with relapsed/refractory CLL.

A second study reported at the meeting demonstrated objective responses in 83% of patients with high-risk CLL who were treated with ibrutinib.

“Ibrutinib has the potential to change the treatment landscape in CLL,” said John C. Byrd, MD, Director of Hematology at The Ohio State University Comprehensive Cancer Center in Columbus during a press conference.

BTK has emerged as a key player in the abnormal B-cell antigen receptor signaling that drives CLL and certain other B-cell diseases. Ibrutinib is one of several BTK inhibitors in development and is the farthest along in clinical investigation.

Dr Byrd presented results from a trial of ibrutinib monotherapy involving 85 patients with previously treated CLL and 31 treatment-naïve patients. All patients received 420 mg daily orally, which was associated with a 68% objective response rate (10% complete response [CR]) in the previously untreated patients and 70% (2% CR) in the relapsed/refractory group. In addition, 13% of the treatment-naïve patients and 4% of patients in the relapsed/refractory group had stable disease.

At 22 months, 96% of the treated sub­­group remained alive, as did 85% of the patients with relapsed/refractory disease.

The second trial involved 40 patients with poor-prognosis CLL. The cohort included patients with a history of poor response to therapy and those with unfavorable genetics, said Jan Burger, MD, PhD, a hematologic oncologist at The University of Texas M.D. Anderson Cancer Center in Houston.

All patients received ibrutinib daily plus weekly infusions of rituximab during the first month, followed by once-monthly infusions thereafter. The regimen resulted in 1 CR, 32 partial responses, 2 minor responses, and no response in 2 patients. Two other patients had not been treated long enough for a response assessment.

Dr Burger characterized the ibrutinib- rituximab combination as highly active, not that several patients had particularly dramatic responses.
In both trials, ibrutinib was associated with low rates of severe toxicity. Dr Byrd reported a 13% incidence of grade 3/4 myelosuppression and grade 3/4 infection in 10% of untreated and 40% of relapsed/refractory patients.

Dr Burger reported 13 cases of grade 3/4 toxicity, including neutropenia, fatigue, pneumonia, insomnia, and bone pain.

Diarrhea was the most common adverse effect associated with ibrutinib in both trials, and cases were grade 1/2 in severity.

“Most side effects were modest and went away after the first couple of cycles of therapy,” noted Dr Byrd.

Related Items
Nelarabine Therapy Up Front Boosts Survival in T-Cell Leukemia and Lymphoma
Phoebe Starr
August 2018 Vol 11, Special Issue published on August 20, 2018 in Leukemia
Next-Generation Sequencing Could Help Treatment Decisions in Acute Myeloid Leukemia
Chase Doyle
August 2018 Vol 11, Special Issue published on August 20, 2018 in Leukemia
Can Technologic Innovations and Formulary Considerations Improve Healthcare Outcomes?
Charles Bankhead
June 2018 Vol 11, No 4 published on June 25, 2018 in Conference Highlights AMCP
ASCO 2017: Chronic Lymphocytic Leukemia Highlights
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights published on August 24, 2017 in Leukemia
In Chronic Myeloid Leukemia, Selection of Tyrosine Kinase Inhibitors Depends on Variables Other Than Survival
Wayne Kuznar
August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights published on August 24, 2017 in Leukemia
Last modified: March 4, 2013
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME